A total of € 63.0 million was used for acquisitions and investments in non-current financial assets (2011: € 171.5 million). Of this amount, € 20.6 million (2011: € 161.0 million) was used for acquisitions. Investments in non-current financial assets totaled € 42.4 million (2011: € 10.5 million). Acquisitions reflect the purchase of CellASIC Corp. and Biochrom AG.
| XLS |
|
|
|
|
€ million |
Total |
|
Purchase price paid |
21.7 |
|
Cash and cash equivalents acquired |
–1.1 |
|
Acquisitions |
20.6 |
In 2012, cash inflows from disposals of assets amounted to € 93.6 million. Cash inflows in 2011 related mainly to the payment of our purchase price receivable of € 270.2 for the sale of Théramex, which closed in December 2010, the divestment of the Crop BioScience business amounting to € 200.9 million, and the sale of Merck Capital Asset Management Limited, Malta, to Merck Pensionstreuhand e.V., Darmstadt, amounting to € 218.1 million.
Net cash outflows from changes in other financial assets amounting to € 725.6 million (2011: € 1,061.2 million) mainly resulted from short-term monetary deposits and the purchase of current financial assets.
search hit 45
